Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AUTL with free AI briefings, catalyst countdowns, and dilution alerts.

AUTL · Autolus Therapeutics plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$248.4M Cash on Hand
34.2mo Cash Runway
Follow AUTL by email Get an email when AUTL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AUTL, unsubscribe in one click. Privacy

📣 What AUTL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
AUTO CAR T cell therapy Patients Followed for up to 15 Years Following Their First Dose of… Phase 2 · NCT03628612 Enrolling by invitation
Obecabtagene Autoleucel Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Phase 1/2 · NCT04404660 Active not recruiting
Autologous BCMA/TACI-targeted CAR T Cells AUTO2 Multiple Myeloma Phase 1/2 · NCT03287804 Terminated
Autologous Anti-CD19/CD22 CAR T-cells AUTO3 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Phase 1/2 · NCT03287817 Terminated
AUTO3 (CD19/22 CAR T cells B Acute Lymphoblastic Leukemia Phase 1/2 · NCT03289455 Completed
Anti-TRBC1-CAR-CD3zeta-4-1BB-RQR8-expressing… T Cell Non-Hodgkin Lymphoma Phase 1/2 · NCT03590574 Terminated
Out-of-specification obecabtagene autoleucel Lymphoblastic Leukemia, Acute, Adult N/A · NCT06799221 Available

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AUTL holds $248.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $21.8M/quarter from operations, an estimated runway of 34.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AUTL files for a raise →

👥 Who Owns AUTL

Insiders 0.5% Other 5%+ holders 24.7% Institutions (106 holders) 56.5% Public and other holders 18.3%
HolderTypeShares% of sharesAs of
MAK Capital Fund LP 5%+ holder (13G) 30,528,859 11.46% 2026-09-30
BXLS V - Autobahn L.P. 5%+ holder (13D) 20,485,611 7.69% 2026-11-06
Renata Kellnerova 5%+ holder (13D) 14,782,275 5.55% 2026-08-27
Armistice Capital, LLC Institution (13G, 5%+) 13,750,000 5.16% 2026-09-30
Christian Itin
Chief Executive Officer, Director
Insider 1,116,009 0.42% 2026-03-18
Christopher Andrew Vann
Chief Operating Officer
Insider 152,211 0.06% 2026-03-18
John E Berriman
Director
Insider 136,331 0.05% 2026-03-18
Cintia Piccina
U.S. CCO & Country Gen Manager · +60,000 options
Insider 13,287 0.00% 2026-09-01
Christopher Michael James Williams
Chief Business Officer
Insider 8,198 0.00% 2026-03-18

Share count 266,340,330 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AUTL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AUTL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.